Company profile for Pharmaxis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Pharmaxis is a research-based specialist pharmaceutical company with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis has been the subject of two large scale clinical trials and is marketed in Europe and Australia. A clinical trial is underway aiming to secure approval for Bronchitol in the United States. Bronchitol is manufactured in Australia by Pharmaxis. ...
Pharmaxis is a research-based specialist pharmaceutical company with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis has been the subject of two large scale clinical trials and is marketed in Europe and Australia. A clinical trial is underway aiming to secure approval for Bronchitol in the United States. Bronchitol is manufactured in Australia by Pharmaxis. Aridol® for the assessment of asthma is approved and sold in Europe, Australia and Asia. Pharmaxis employs a team of research scientists leading the company’s development pipeline of products.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
Pharmaxis Ltd 20 Rodborough Rd Frenchs Forest NSW 2086
Telephone
Telephone
61 2 9454 7200
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Aptar takes up option on Orbital high dose dry powder inhaler
Aptar takes up option on Orbital high dose dry powder inhaler

09 Aug 2022

// Nick Paul Taylor FIERCEPHARMA

https://www.fiercepharma.com/pharma/aptar-takes-option-orbital-high-dose-dry-powder-inhaler-pursuit-halcyon-drug-delivery-days

Nick Paul Taylor FIERCEPHARMA
09 Aug 2022

https://www.contractpharma.com/contents/view_breaking-news/2022-08-05/aptar-pharma-acquires-worldwide-rights-to-pharmaxis-orbital-inhaler/?widget=listSection

CONTRACTPHARMA
05 Aug 2022

https://www.prnewswire.com/news-releases/fda-clears-pharmaxis-cancer-drug-to-progress-to-phase-2-study-in-liver-cancer-301419232.html

PRNEWSWIRE
09 Nov 2021

https://www.prnewswire.com/news-releases/pharmaxis-cleared-to-progress-to-phase-2-bone-marrow-cancer-trial-301392552.html

PRNEWSWIRE
05 Oct 2021

https://www.prnewswire.com/news-releases/pharmaxis-treatment-to-prevent-wound-and-burns-scars-clears-phase-1-trial-301365745.html

PRNEWSWIRE
31 Aug 2021

https://www.contractpharma.com/contents/view_breaking-news/2021-08-17/aptar-pharma-pharmaxis-enter-orbital-dpi-agreement/?widget=listSection

CONTRACT PHARMA
17 Aug 2021

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty